As CMOs wait to see the short-term fallout of the Pfizer-Allergan deal, an M&A expert says contract manufacturing will follow the CRO industry in embracing strategic alliances and consolidation.
Preclinical CRO Biopta will add stem cell programming tech to its offering, expand in Japan and nearly double its workforce under new owner, Reprocell.
Inconsistent practices and a lack of trust are restricting sponsors from fully realising the potential of CRO strategic partnerships, according to Tufts' Director Kenneth Getz.
Restarting production at the former Ben Venue facility in Ohio will be a “significant task” says Xellia Pharmaceuticals which plans to invest after buying the site from Hikma.
Eisai will sell its clinical diagnostics business – EIDIA Co. Ltd - to Sekisui Chemical for JPY 22.4bn ($183m).
Cyprotex has expanded its toxicology offering with a new in silico tech it claims will reduce preclinical costs and cut the number of animal studies required.